Protalix BioTherapeutics (PLX) Accumulated Expenses (2011 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Accumulated Expenses of $2.4 million for Q1 2026, down 73.82% year-over-year from $9.3 million in Q1 2025, and up 6.02% quarter-over-quarter from $2.3 million in Q4 2025.
Protalix BioTherapeutics (PLX) Accumulated Expenses (2011 - 2026) Analysis & Trends
Protalix BioTherapeutics' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 73.82% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 73.82% YoY), while the FY2025 annual figure was $2.3 million, down 75.87% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $2.4 million, up from $2.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $9.6 million in Q4 2024, with the low at $745000.0 in Q3 2025.
- The 4-year median for Accumulated Expenses is $2.3 million (2025), against an average of $3.9 million.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 496.14% in 2024, then plunged 75.87% in 2025.
- Protalix BioTherapeutics' Accumulated Expenses stood at $1.6 million in 2023, then surged by 496.14% to $9.6 million in 2024, then slumped by 75.87% to $2.3 million in 2025, then advanced by 6.02% to $2.4 million in 2026.
- Business Quant data shows PLX's Accumulated Expenses at $2.4 million in Q1 2026, $2.3 million in Q4 2025, and $745000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.96 Mn |
| Mar 31, 2026 | 2.45 Mn |
| Dec 31, 2025 | 2.31 Mn |
| Sep 30, 2025 | 745,000.00 |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | 9.35 Mn |
| Dec 31, 2024 | 9.57 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Dec 31, 2018 | 6.37 Mn |
| Dec 31, 2017 | 4.80 Mn |
| Dec 31, 2016 | 3.58 Mn |
| Dec 31, 2015 | 1.57 Mn |
| Dec 31, 2014 | 3.11 Mn |
| Dec 31, 2013 | 1.79 Mn |
| Dec 31, 2012 | 2.03 Mn |
| Dec 31, 2011 | 2.33 Mn |